| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232;
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32608; and
University of Memphis Integrated Microscopy Center, Memphis, TN 38152
The roles of IgG and secretory IgA in the protection of the respiratory tract (RT) against influenza infection remain unclear. Passive immunization with Ab doses resulting in serum IgG anti-influenza virus Ab titers far in excess of those observed in immune mice has compounded the problem. We compared the effects of i.v. anti-influenza virus IgG and i.v. anti-influenza virus polymeric IgA (pIgA) mAb administered in amounts designed to replicate murine convalescent serum or nasal Ab titers, respectively. A serum anti-influenza virus IgG titer 2.5 times the normal convalescent serum anti-influenza virus IgG titer was required for detectible Ab transudation into nasal secretions, and a serum IgG titer 7 times normal was needed to lower nasal viral shedding by 98%. Anti-influenza virus pIgA at a nasal Ab titer comparable to that seen in convalescent mice eliminated nasal viral shedding. The RT of influenza-infected pIgA- or IgG-protected mice were studied by scanning electron microscopy. Only pIgA was found to prevent virally induced pathology in the upper RT, suggesting that IgG did not prevent viral infection of the nose, but neutralized newly replicated virus after infection had been initiated. In contrast, IgG, but not pIgA, was found to prevent viral pathology in the murine lung. Our results help to resolve the controversy of IgA- vs IgG-mediated protection of the RT; both Abs are important, with plasma IgG Ab serving as the back-up for secretory IgA-mediated protection in the nasal compartment, and IgG being the dominant Ab in protection of the lung.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  F. Zhou, A. Goodsell, Y. Uematsu, and M. Vajdy Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant Clin. Vaccine Immunol., April 1, 2009; 16(4): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Chen, Tae Jin Kang, A. K. Bhattacharjee, and A. S. Cross Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia Innate Immunity, October 1, 2008; 14(5): 269 - 278. [Abstract] [PDF]
|
|
|
|
 |
|
 D. N. Wolfe, G. S. Kirimanjeswara, E. M. Goebel, and E. T. Harvill Comparative Role of Immunoglobulin A in Protective Immunity against the Bordetellae Infect. Immun., September 1, 2007; 75(9): 4416 - 4422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Mantis, J. Palaia, A. J. Hessell, S. Mehta, Z. Zhu, B. Corthesy, M. R. Neutra, D. R. Burton, and E. N. Janoff Inhibition of HIV-1 Infectivity and Epithelial Cell Transfer by Human Monoclonal IgG and IgA Antibodies Carrying the b12 V Region J. Immunol., September 1, 2007; 179(5): 3144 - 3152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pueschel, A. Tietz, M. Carsillo, M. Steward, and S. Niewiesk Measles Virus-Specific CD4 T-Cell Activity Does Not Correlate with Protection against Lung Infection or Viral Clearance J. Virol., August 15, 2007; 81(16): 8571 - 8578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ferko, C. Kittel, J. Romanova, S. Sereinig, H. Katinger, and A. Egorov Live Attenuated Influenza Virus Expressing Human Interleukin-2 Reveals Increased Immunogenic Potential in Young and Aged Hosts J. Virol., December 1, 2006; 80(23): 11621 - 11627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wiley, M. P. Tighe, and A. G. Harmsen Upper Respiratory Tract Resistance to Influenza Infection Is Not Prevented by the Absence of Either Nasal-Associated Lymphoid Tissue or Cervical Lymph Nodes J. Immunol., September 1, 2005; 175(5): 3186 - 3196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Ko, H.-J. Ko, W.-S. Chang, S.-H. Park, M.-N. Kweon, and C.-Y. Kang {alpha}-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor J. Immunol., September 1, 2005; 175(5): 3309 - 3317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-E. Johansen, E. S. Baekkevold, H. S. Carlsen, I. N. Farstad, D. Soler, and P. Brandtzaeg Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils Blood, July 15, 2005; 106(2): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
